Atazanavir (Reyataz®) for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-naive patients
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000422
English
Authors' recommendations:
Atazanavir (Reyataz®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-naive patients, in accordance with British HIV Association (BHIVA) guidance.
Atazanavir (Reyataz®) is not suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2008
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=111769&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Adult
- HIV
- HIV-1
- Oligopeptides
- Pyridines
- Anti-HIV Agents
- HIV Infections
- Drug Therapy, Combination
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.